Panel Topics and Speaker Profiles

Biotechnology and the Emerging Human Rights Framework

“Developments in human biotechnology continue at an often astounding pace,” the United Nation’s High Commissioner for Human Rights has noted. “As the significant benefits offered by these new techniques are becoming clear, so too are the concerns they raise for many people in terms of respect for human life and human dignity. Human rights have an important role to play in dealing with these issues by providing a framework through which the rights of all interested actors can be taken into account.” In this session, Professor Alexander Capron and our panelists will examine the emergence of a human rights framework, against which the actions of global biopharmaceutical companies increasingly are judged.

Alexander Capron
UCLA School of Law

Alexander Capron, University Professor, is holder of the Scott H. Bice Chair in Healthcare Law, Policy and Ethics, and Professor of Law and Medicine at USC. Professor Capron is a globally-recognized expert in health policy and medical ethics. He teaches Torts; and Law, Science, and Medicine. He also teaches at the USC School of Medicine and is co-director of the Pacific Center for Health Policy and Ethics, a campus-wide interdisciplinary research and education center. He returned to USC Law in fall 2006 after four years on leave as director of Ethics, Trade, Human Rights and Health Law at the World Health Organization in Geneva. Professor Capron’s publications include Law, Science and Medicine 2nd ed. (with others, Foundation Press, 1996), Treatise on Health Care Law (with others, Matthew Bender, 1991), and Genetics, Ethics and Human Values (edited with Z. Bankowski, Geneva: CIOMS, 1991). Professor Capron received a B.A. from Swarthmore College and an LL.B. from Yale University, where he was an editor of the Yale Law Journal. He was appointed by President Bill Clinton to the National Bioethics Advisory Commission, where he served for five years; is a trustee of The Century Foundation and president of the International Association of Bioethics; and is a member of the Institute of Medicine.

Lisa Conte
Napo Pharmaceuticals, Inc.

Ms. Conte is responsible for strategy development, partnerships, recruitment, fundraising, and investor and public relations at Napo Pharmaceuticals, and has been its Chief Executive Officer since its founding. Prior to founding Napo, she founded Shaman Pharmaceuticals, Inc., a natural product pharmaceutical company, in 1989. As CEO of several companies, she has raised over US$220 million (including leading an IPO). From 1987 to 1989 Ms. Conte was a Vice President at Technology Funding, Inc., a venture capital firm where she was responsible for the analysis and management of health care industry investments. From 1985 to 1987 she conducted risk and strategy audits for start-up healthcare companies at Strategic Decisions Group, a management consulting firm. While studying for her MBA, Ms. Conte interned at Eli Lilly & Company, where she worked with their internal venture capital group to identify promising new biotechnology companies. Ms. Conte received her AB in Biochemistry from Dartmouth College, her MS in Physiology/Pharmacology from the University of California at San Diego and her MBA from the Amos Tuck School, Dartmouth College. She is the recipient of several entrepreneurship awards, including the 1994 E&Y Entrepreneur of the Year Award, and has sat on several industry boards.
Aron Cramer*

Business for Social Responsibility

Aron Cramer is President and CEO of Business for Social Responsibility (BSR). Prior to assuming the post of President and CEO, he was been based in Paris, where he launched BSR’s Europe office in 2002. He also led the establishment of BSR’s Hong Kong office in 2001. Cramer joined BSR in 1995, and served as the founding director of its Business and Human Rights Program. Cramer has worked closely with dozens of BSR’s member companies in numerous industry sectors, providing advice and counsel on the full spectrum of CSR issues, including Ford Motor Co., ChevronTexaco, Nike, Unilever, Royal Dutch/Shell, Novartis, Novo Nordisk and Rio Tinto. He also has provided support and counsel to many of the leading CSR initiatives in recent years, including the UN Global Compact, the Global Reporting Initiative, the Voluntary Principles on Security and Human Rights, and the Fair Labor Association. He has worked extensively with the World Bank, the US Agency for International Development and other public institutions. Prior to joining BSR, Cramer served as an attorney in private practice in San Francisco, and at ABC News in New York. He is a graduate of Tufts University, and obtained his law degree from the University of California, Berkeley. He was born and raised in Los Angeles. Cramer speaks frequently before industry audiences and in other fora, and has been widely quoted in media outlets including the New York Times, Los Angeles Times, National Public Radio and others. In 2004, he co-edited Raising the Bar, a publication providing guidance on implementation of the UN Global Compact principles.

Carol A. Dahl*

Bill and Melinda Gates Foundation

Dr. Carol Dahl directs the Bill and Melinda Gates Foundation’s Global Health Technologies initiative, which makes grants to achieve fundamental scientific advances in global health that could lead to new ways to prevent, treat, and diagnose disease. Prior to joining the foundation in 2003, Dahl served as vice president for strategic partnerships at Biospect, Inc., a company developing technology to inform the diagnosis and clinical management of patient health. From 1990 to 2001, Dahl worked in several capacities at the U.S. National Institutes of Health. In 1998, she guided the creation of the Office of Technology and Industrial Relations at the National Cancer Institute (NCI) and served as its first director through 2001. Previously, she served as assistant to the director of NCI, advising on technology development opportunities in support of the National Cancer Program, and as program director for the Sequencing Technology Branch at the National Center for Human Genome Research. Dahl also supported the development of the biotechnology portfolio of the Advanced Technology Program of the National Institutes of Standards and Technology. Dahl received a bachelor’s degree from the University of Iowa, and master’s and doctoral degrees from the University of Wisconsin-Madison. She received postdoctoral training at the Karolinska Institute in Stockholm and the Immunobiology Research Center at the University of Minnesota, and served on the faculty of the Pittsburgh Cancer Institute.
A “Reorientation” – From Bioethics to Human Rights?

Concerns raised for some people by the advent of new biotechnologies typically have been debated (frequently ad infinitum) within a bioethics framework -- respect for autonomy, nonmaleficence, beneficence, and justice. According to Professor George Annas, however, bioethics “is likely to have no real-world future without a significant reorientation of its focus and direction. . . . [T]he most useful reformulation involves recognition and engagement with two interrelated forces reshaping the world and simultaneously providing new frameworks for ethical analysis and action, globalization and public health. Most relevant for American bioethics is that globalization brings with it a new focus on international human rights law, and its aspirations as articulated in the Universal Declaration of Human Rights.” In this session, Professor Ruth Macklin and a distinguished panel of experts will consider the existence and merits of a “reorientation” from bioethics to human rights. Are ethical and human rights approaches different? When examining the biotechnology industry and its practices, will the application of ethical norms and human rights produce different results?

Ruth Macklin  
*Albert Einstein College of Medicine*

Ruth Macklin is Professor of Bioethics at Albert Einstein College of Medicine in the Bronx, New York. She is a graduate of Cornell University and received her Ph.D. in Philosophy from Case Western Reserve University. She has more than one hundred thirty scholarly publications, as well as articles in magazines and newspapers for general audiences. She is author or editor of ten books, including *Mortal Choices* (Houghton Mifflin, 1988), *Enemies of Patients* (Oxford, 1993), and *Surrogates and Other Mothers* (Temple, 1994). Her publications include articles on AIDS, human reproduction, the ethics of human subjects in research, and topics in health policy. She is an elected member of the Institute of Medicine of the National Academy of Sciences and is co-chair of the National Advisory Board on Ethics in Reproduction. She serves on the Executive Board of the American Association of Bioethics, is Vice-President of the International Association of Bioethics, and serves as an adviser to the World Health Organization.

Rosario Isasi  
*Université de Montréal*

Rosario Isasi is currently a Postdoctoral Fellow for the Centre de recherche en droit public (CRDP), Université de Montréal. Her research interests intersect public health, ethics, law and science. She has particular expertise in the area of comparative legal and ethical research regarding cloning and stem cell research. Ms. Isasi is the Academic Secretary of the International Stem Cell Forum Ethics Working Party, an affiliated scholar of the Center for Genetics and Society in Oakland, California and the Institute on Biotechnology and the Human Future, Chicago-Kent College of Law, in Chicago, Illinois. She is also a member of the Advisory Board of Global Lawyers and Physicians, a transnational professional association of lawyers and physicians working together to promote human rights and health. She holds her J.D. from the Pontifical Catholic University of Peru, where she practiced corporate and health law. She received her Master of Public Health from Boston University, USA.

Josephine Johnston  
*The Hastings Center*

Josephine Johnston, a New Zealand-trained lawyer with a Masters in bioethics and health law from the University of Otago, joined the staff as Associate for Ethics, Law, and Society on August 1, 2003. Before coming to the Hastings Center, Ms. Johnston worked on ethical and legal issues in gene therapy and stem cell research at Dalhousie University's Department of Bioethics in Halifax, Canada, where she was funded by the Canadian Institutes of Health Research and the Stem Cell Network of Canada. She also spent a year as the research assistant for the NIH grant “Ethnicity, Citizenship, Family: Identity after the Human Genome Project” at the University of Minnesota’s Center for Bioethics. She has taught a variety of ethics and law classes in the medicine, dentistry, and law schools at Minnesota and the University of Otago. Before undertaking her Master’s, she practiced law in both New Zealand and Germany. At the Hastings Center
Ms. Johnston’s research currently focuses on the potential for patents to act as barriers to access essential medicines and biological materials such as genes and stem cells, as well as on the ethical issues arising in the management of financial conflicts of interest in biomedical research. She remains interested in stem cell research generally and in body modification surgeries, about which she wrote her Master's thesis. Ms Johnston also directs the Centers visiting scholar and intern programs.

Debra Aronson  
Biotechnology Industry Organization (BIO)

Debra Aronson is director of bioethics for the Biotechnology Industry Organization. BIO is the largest trade organization to serve and represent the biotechnology industry in the United States and around the globe. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers, and related organizations in the United States. At BIO, Debra Aronson has been a constant and effective voice for industry and its commitment to the socially responsible use of biotechnology in health care, food and agriculture, industry and the environment. As biotechnology reaches toward such benefits as treatments for intractable diseases such as cancer, Alzheimer’s and Parkinson’s; abundant, nutritious food; industrial sustainability; and a cleaner world, Ms. Aronson and BIO have encouraged public discussion of the ethical, legal and social implications of biotechnology research.

The Corporation and its Obligations

Do biotech and other companies have responsibilities beyond obeying the law and maximizing shareholder value? Proponents of “corporate social responsibility” argue that all organizations, including for-profit businesses, owe a duty of care to stakeholders in all aspects of their operations. For some, this duty is heightened for companies which sponsor human subjects research and market healthcare-related products. Indeed, Professor Klaus Leisinger has argued that enlightened companies should adopt a human rights-aware approach. “No company competing with integrity,” he notes, “can justify ‘collateral human rights damage’ in its endeavors to achieve its profit targets.” And yet, is it reasonable to expect that biotech executives, facing enormous scientific and financial challenges, can practically and adequately be responsible for human rights? In this session, Professor Christopher MacDonald and a panel of experts will consider the obligations, if any, of biotechnology corporations to advocate for, and support, human rights norms.

Christopher MacDonald  
St. Mary’s University

A philosopher and ethicist, Chris MacDonald is an Associate Professor (Tenured) in the Philosophy Department at Saint Mary’s University (Halifax, Canada). In 2004 he was awarded a 3-year Ethics Operating Grant by the Canadian Institutes of Health Research, to support a project entitled, “Biotech Ethics: Corporate Decisions as Key to Better Health and Better Health Policy.” In early 2006, Chris was awarded a 3-year Standard Research Grant by the Social Sciences and Humanities Research Council (of Canada), to support a project entitled, "External Perspectives on Corporate Moral Motivation." Dr. MacDonald conducts research in business and professional ethics and health care ethics (currently focusing on ethical issues in the biotechnology and nanotechnology industries) and foundational issues in moral theory. He is a former Post-Doctoral Fellow in the Department of Bioethics, Dalhousie University, and former Graduate Research Associate at the University of British Columbia’s Centre for Applied Ethics. He also runs a popular business ethics blog, www.ethicsweb.ca.
Victoria Hale*
Institute for OneWorld Health

Victoria Hale is Founder, Chief Executive Officer and Chair of the Board of Directors of the Institute for OneWorld Health. Dr. Hale established her expertise in all stages of biopharmaceutical drug development at the US Food and Drug Administration (FDA), Center for Drug Evaluation and Research; and at Genentech, Inc., the world's first biotechnology company. She presently maintains an Adjunct Associate Professorship in Biopharmaceutical Sciences at the University of California, San Francisco (UCSF), is an Advisor to the World Health Organization (WHO) for building ethical review capacity in the developing world, and has served as an expert reviewer to the National Institutes of Health (NIH) on the topic of biodiversity. Dr. Hale's recent honors include being named a 2006 John D. and Catherine T. MacArthur Foundation Fellow. Other recent achievements include selection as an Ashoka Fellow by Ashoka for work in leading social innovation (2006), Executive of the Year by Esquire Magazine (2005), receiving The Economist Innovation Award for Social and Economic Innovation (2005), and the Skoll Award for Social Entrepreneurship from the Skoll Foundation (2005). She was named one of the "Most Outstanding Social Entrepreneurs" by the Schwab Foundation for Social Entrepreneurship in Switzerland (2004). In 2004, Dr. Hale and OneWorld Health were included in the Scientific American 50, the magazine's annual list recognizing outstanding acts of leadership in science and technology.

Lawrence E. Mitchell*
The George Washington University Law School

Lawrence E. Mitchell is the Theodore Rinehart Professor of Business Law at the George Washington University Law School. Professor Mitchell joined the Law School faculty in 1991. For six years before entering academia, Professor Mitchell practiced corporate law in New York City. His teaching and scholarly interests include corporate law and finance, and jurisprudence. Professor Mitchell has had articles on corporate law and on jurisprudence published in a number of leading law reviews. He is the editor of Progressive Corporate Law (1995), and co-author of the casebook, Corporate Finance and Governance, with Lawrence Cunningham and Jeffrey Haas. He also has a forthcoming casebook on corporate law, which he co-authored with GW Law Professor Dalia Tsuk. His book Stacked Deck: A Story of Selfishness in America was published by Temple University Press in 1998 and was submitted for the Pulitzer Prize in general non-fiction. In 2002, Yale University Press published his most recent book, Corporate Irresponsibility: America's Newest Export, which was also submitted by the publisher for a Pulitzer Prize. Professor Mitchell recently has done substantial work using economic sociology to address corporate law issues, and currently is at work on his next book, a history of the development of American corporate capitalism from the late nineteenth century to the present. Professor Mitchell is director of the Sloan Program for the Study of Business in Society and the International Institute for Corporate Governance and Accountability.
Human Rights for “Redesigned” Humans

Biotechnological advances are likely to bring far-reaching and, for some, controversial changes to our existence and self-conception as “humans.” While some governments, religious groups and technology critics may attempt to prevent or constrain these changes, it is likely that genetics, nanotechnology, robotics and, especially, their combination, will present us with significant moral dilemmas. To the extent that biotechnology contributes to a “redesign” of humans, what impact will these changes have on our notions of human rights? The symposium concludes with a discussion among Professor Gregory Stock and other thinkers on the nature of human rights, and biotechnology’s human rights obligations, in a trans/post-human future.

Gregory Stock
UCLA School of Public Health

Gregory Stock is the Director of the Program on Medicine, Technology, and Society at UCLA’s School of Public Health. In this role he explores critical technologies poised to have large impacts on humanity’s future and the shape of medical science. His goal has been to bring about a broad public debate on these technologies and their implications, leading to wise public policies surrounding their realization. Of particular interest to the program are the implications for society, medicine, and business of the human genome project and associated developments emerging from today’s revolution in molecular genetics and bioinformatics. The Storefront Genome, the symposium he convened in January 2003 to consider the broad challenges that cheap, easy access to our genetic constitutions will bring drew wide media attention, and his 1998 book, Redesigning Humans: Our Inevitable Genetic Future with Houghton Mifflin, won the Kistler Book Prize for Science books and was nominated for a Wired Rave Award. Among his other books are Engineering The Human Germline for Oxford University Press, Metaman, for Simon & Schuster, and the best seller, The Book of Questions, which has been translated into seventeen languages, and is now in its fifty-fifth printing. Sequels to that book include The Book of Questions: Business, Politics, and Ethics and a new book that will explore how coming technologies will reshape our everyday lives. Dr. Stock has been an invited speaker to numerous academic, government, and business conferences, sits on the editorial board of the American Journal of Bioethics, and was asked to submit an Advisory Memo to the President on the challenges of the next century. He makes regular appearances on television and radio, including CNN, PBS, NPR, Bloomberg, and the BBC. He has debated biotech policy with Jeremy Rifkin, Leon Kass, Francis Fukuyama, and other prominent voices who would rein in biomedical research, and he is hosting a television special later this year on key figures in today’s biotech revolution.

Stephen Marks
Harvard School of Public Health

Stephen Marks is the François-Xavier Bagnoud Professor of Health and Human Rights in the Department of Population and International Health of the Harvard School of Public Health. The emphasis of Stephen Marks’s work is on the interface of health and human rights, drawing on the disciplines of international law, international politics, international organizations, and international economics. Professor Marks’s current interests include integrating human rights into sustainable human development and developing human rights indicators of relevance to poverty reduction strategies. He has been a consultant to the United Nations Development Program on this topic and expects to collaborate on a new project for UNICEF with Professor Ajay Mahal. Previously he was principal investigator for a major grant by the Government of the Netherlands on the right to development. The aim of this research is to introduce human rights concepts into development planning and implementation at the national and international levels. One product of this research was an article on “The Right to Development: Between Rhetoric and Reality” in the Harvard Human Rights Journal. He
is working on two books emerging from this project, in close collaboration with the Independent Expert on the Right to Development, Dr. Arjun Sengupta, who is also an adjunct professor at HSPH. He and Dr. Sengupta, who was recently appointed Independent Expert on Extreme Poverty and Human Rights, are working on new projects focusing on poverty. Most relevant to this year’s KGI Bioethics Symposium, Professor Marks’ interests include the relation between bioethics and human rights. He is working with Professor Daniel Wikler on several projects aimed at bridging the disciplinary boundaries between ethics and human rights. He wrote the entry on "human rights" for the third edition of the Encyclopedia of Bioethics and on "medical experimentation" for the Encyclopedia on Genocide and Crimes Against Humanity. Professor Marks has numerous advanced degrees, including a Doctor of Laws (Docteur d'État en droit), with high honors, Institute of the Law of Peace and Development, Faculty of Law and Economics, University of Nice; a Master of Arts (hon.) from Harvard University; and an advanced degree (Diplôme d'études appliquées avancées, DEAA) in administrative litigation and human rights, from the Faculty of Law, Economics and Political Science of the University of Besançon.

**Ronald Bailey**

*Reason Magazine*

Ronald Bailey is the award-winning science correspondent for *Reason*, the libertarian monthly named one of "The 50 Best Magazines" three out of the past four years by the Chicago Tribune. Established in 1968 and a four-time finalist for National Magazine Awards, Reason has a print circulation of 40,000 and won the 2005 Western Publications Association "MAGGIE" Award for best political magazine. *Reason Online*, the magazine's Web edition, draws 1.75 million visits per month, and the staff weblog Hit & Run has been named by *Playboy*, *Washingtonian*, and others as one of the best political blogs. He is the author of the new book Liberation Biology: The Moral and Scientific Case for the Biotech Revolution (Prometheus), and his work appears in the The Best American Science and Nature Writing 2004. Prior to joining Reason in 1997, Bailey produced several weekly national public television series, including Think Tank and TechnoPolitics, as well as several documentaries for PBS television and ABC News. In 1993, he was the Warren T. Brookes Fellow in Environmental Journalism at the Competitive Enterprise Institute. From 1987-1990, Bailey was a staff writer for *Forbes*, covering economic, scientific and business topics. His articles and reviews have appeared in *The New York Times*, *The Wall Street Journal*, *The Washington Post*, *Commentary*, *Smithsonian*, *TechCentralStation*, *National Review*, *Readers Digest*, and many other publications. Bailey won a 2004 Southern California Journalism Award for best magazine feature for his story, "The Battle For Your Brain," which delved into the ethical and political conflicts over new brain enhancement technologies. Bailey is the editor of Global Warming and Other Eco-Myths: How the Environmental Movement Uses False Science to Scare Us to Death (Prima Publishing, 2002), Earth Report 2000: Revisiting The True State of The Planet (McGraw Hill, 1999), and The True State of the Planet (The Free Press, 1995). He is the author of ECOSCAM: The False Prophets of Ecological Apocalypse (St. Martin’s Press, 1993). Bailey has appeared on many television and radio programs, including the NBC Nightly News, National Public Radio’s To the Point and Marketplace, and various C-SPAN programs. He has lectured at Harvard University, Yale University, Morehouse University, the Massachusetts Institute of Technology, Rutgers University, the University of Virginia, and many other places. In 2004, he testified before a congressional committee on "The Impact of Science on Public Policy.” He is a member of the Society of Environmental Journalists and the American Society for Bioethics and Humanities. He is also an adjunct scholar at the Competitive Enterprise Institute and the Cato Institute.
**The discussion continues**

**Biotechnology’s Responsibility for Human Rights?**

Following KGI’s Bioethics Symposium on April 17, our discussion concerning biotechnology and human rights will continue at the Biotechnology Industry Organization’s International Convention in Boston, on May 7, 2007, as part of the Convention’s *Bioethics Track* programming.

**George Annas**  
*Boston University School of Public Health*

George J. Annas is the Edward R. Utley Professor of Health Law, Bioethics & Human Rights, Chairman of Department of Health Law, Bioethics & Human Rights, at the Boston University School of Public Health. He holds a degree in economics from Harvard College and law from Harvard Law School and an M.P.H. from the Harvard School of Public Health. He is a widely published national expert in the field of health law, bioethics, and human rights, whose books include *The Rights of Patients*, "Judging Medicine", *Some Choice: Law, Medicine and the Market*, and *American Bioethics: Crossing Human Rights and Health Law Boundaries.* Professor Annas is the cofounder of Global Lawyers and Physicians, a transnational professional NGO dedicated to promoting human rights and health. Professor Annas teaches health law and human rights courses in the Boston University School of Public Health, the Boston University School of Law, and the BU Medical School. He is a member of the Board of Directors of the Council for Responsible Genetics and the Indigenous Peoples Council on Biocolonialism, as well as a member of the Institute of Medicine.

**Simon Best**  
*BioIndustry Association (UK)*

Simon Best is chairperson of the BioIndustry Association (UK). He is the co-founder and Chairman of Ardana Biosciences PLC, Chairman of ICRISAT and the Edinburgh University Technology Fund, non-Executive Chairman of Neuro3D, non-Executive Director of Avestha Gengraine Technologies, and a Director of the Doyle Foundation and the Hebrides Ensemble. Dr. Best served as a member of the Board of the Biotechnology Industry Organization (BIO) from 1998-2005 and as a Governor of the Food and Agriculture Section of the World Economic Forum (WEF) from 1994-98. In September 1999, he was nominated as "Science and Technology Venturer of the Year" by the Financial Times. Mr. Best is an Industry Adviser to BIO Ventures for Global Health (BVGH), which was spun out of BIO with support from the Bill & Melinda Gates and Rockefeller Foundations. Dr. Best holds a degree from the University of York and has an M.B.A. from London Business School. In 2004, he was awarded an Honorary Doctorate from the University of York.
Steven H. Holtzman  
*Infinity Pharmaceuticals, Inc.*

Steven H. Holtzman is a founder, and has served as Infinity’s Chief Executive Officer since the Company’s inception. From early 1994 through mid 2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals. In this role, at various times he had management responsibility for the Company’s activities in the areas of: business development, M&A, licensing, intellectual property and corporate law, human resources, finance, corporate and government affairs, bioethics, public policy, media relations, investor relations, and corporate communications. Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder, the first employee, and Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical, and pharmaceutical applications of transgenic animal technology. Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation’s first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970’s, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K. Mr. Holtzman co-founded and from 1995-2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996-2001, he served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. He is a member of the Board of Directors of Archemix Corporation and Anadys Pharmaceuticals, Inc. He is a Trustee of The Hastings Center for Bioethics and a Trustee of the Berklee College of Music. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Bernd Kasemir  
*Sustainserv, Inc.*

Dr. Bernd Kasemir is a Founding Director of sustainserv, a management consulting firm with offices in Boston and Zurich that focuses on linking sustainability and business. He received his education in the natural sciences at universities in Germany, Switzerland and the United Kingdom. As a Research Fellow at Harvard University’s John F. Kennedy School of Government, he worked on sustainability in the financial industry. He has managed a major EU project on urban lifestyles and energy use, and received business training at the International Institute for Management Development (IMD), Lausanne, Switzerland.

**KGI Bioethics Symposium and BIO Bioethics Track Moderator**

Gary A. Cohen  
*Keck Graduate Institute of Applied Life Sciences*

Gary A. Cohen, the Joseph and Bi Jacobs Visiting Professor of Biotechnology Law and Ethics at the Keck Graduate Institute of Applied Life Sciences, has 20 years’ experience representing industry-leading biotechnology companies. His most recent position was vice president, ethics and corporate responsibility, at Millennium Pharmaceuticals where he was responsible for coordinating both in-house and external programs in bioethics, business ethics and corporate social responsibility. Prior to joining Millennium, Professor Cohen was vice president and general counsel at Genzyme Transgenics Corporation, and senior counsel at Genetics Institute, Inc. He also practiced law with Palmer & Dodge, served as a foreign legal advisor with Yuasa and Hara, and worked for Goldstein & Manello. Professor Cohen received his BA from Washington University in St. Louis, a law degree from Columbia University, and an MPH degree with a concentration in health law, bioethics and human rights from the Boston University School of Public Health.